<DOC>
	<DOCNO>NCT02960711</DOCNO>
	<brief_summary>Phase III randomize control trial men woman Metabolic syndrome ( MetS ) test hypothesis comprehensive life-style change and/or metformin treatment prevent age-related chronic non-communicable disease ( ArCD ) . The aim present study evaluate effect comprehensive life-style intervention ( include moderate physical activity Mediterranean/macrobiotic diet moderate calorie protein restriction ) , treatment Metformin ( calorie restriction mimetic drug ) prevention ArCD .</brief_summary>
	<brief_title>Metformin Dietary Restriction Prevent Age-related Morbid Events People With Metabolic Syndrome</brief_title>
	<detailed_description>Phase III randomize control trial men woman MetS test hypothesis comprehensive life-style change and/or metformin treatment prevent ArCD . Design : 2x2 factorial : 2,000 volunteer randomize four equal group 500 , allocate follow treatment : METFORMIN ( 1700MG/DAY ) + ACTIVE LIFESTYLE INTERVENTION PLACEBO + ACTIVE LIFESTYLE INTERVENTION METFORMIN ( 1700 mg/day ) alone PLACEBO alone The metformin /placebo component study double blind .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Age 5574 , waist circumference equal great 85 cm woman 100 cm men , plus least two factor among define MetS Diagnosed diabetes ( baseline fast glycemia 7mmol/L baseline examination ) Cancer ( except skin carcinoma ) diagnose last 5 year , treatment Excessive frailty : absence agreedupon measurement parameter cutoff point , investigator exclude subject low 5th percentile muscular mass distribution estimate impedance previous study Conditions contraindicate use MET might favour lactic acidosis : Renal , cardiac , hepatic , respiratory insufficiency Serum creatinine &lt; 124Î¼mol/L , proteinuria baseline examination Current treatment Ksparing diuretic , proton pump inhibitor Excessive alcohol consumption Distressing side effect MET treatment . Nausea diarrhoea typically occur one third patient receive MET first time full dose . To avoid dropouts gastrointestinal discomfort treat volunteer half plan dose one month order exclude intolerant subject randomization . Participants randomized intervention group continue take half dose one month shift full dose .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>